DMRA | Ticker Profile - Titan Protect

DMRA

Damora Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$21.01

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.98

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-89.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$45.00

+114% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

https://www.damoratx.com

Country: United States Employees: 7 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.777

Good returns relative to risk taken

Kelly Fraction

0.1210

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.331

Drawdown risk outweighs the returns — higher risk profile

Annual Return

28.3%

Historical annualised return based on price data

Max Drawdown

-85.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.51

Significantly more volatile than the market

52W High

$38.33

45% below the year high

52W Low

$2.45

758% above the year low

Avg Volume

290,890

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.5%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.68

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

22.49

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

22.42

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-8,693,750

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-235,088,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$51.00

Target Median

$45.00

Target Low

$40.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go